Kazia Therapeutics
Kazia Therapeutics

Kazia Therapeutics

Biotechnology
WebsiteInvestor RelationsSEC
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.

$141.6M

Market Cap • 9/22/2026

1994

(32 years)

Founded

1999

(27 years ago)

IPO

NASDAQ

Listing Exchange

Flag of Australia

Australia

Country

Valuation

P/B

4,3

P/S

15,1

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

172,1

EPS

—

Market Cap

Market Cap

141,6M

EV

120,5M

EV/Revenue

12,9

EV/EBITDA

-32,2

EV/EBIT

-32,2

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-38,6%

Total Yield

-38,6%

Payout

0%

Retained Earnings

-58,8M

Profitability

Gross Margin

71,3%

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

0%

Capex/Revenue

0%

Capex/D&A

0%

Capex/OCF

0%

SBC/OCF

—

% PPE

14,7%

% Goodwill

0%

ROE

—

ROIC

—

Growth

CAGR Revenue 5Y

106,6%

CAGR Op. Income 5Y

-16,3%

CAGR Net Income 5Y

-21,6%

CAGR EPS 5Y

-15,6%

CAGR OCF 5Y

-7,3%

Leverage

N.D./EBITDA

5,8

Debt/Equity

0%

Current Ratio

8,6

Quick Ratio

7,4

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium